• Pricing of $US 200 million public offering of 34,782,609 shares at $US 5.75 per share
• Grants underwriters 30-day option to purchase up to 5,217,391 additional shares
• Concurrent $US 90 million private placement to Medtronic

Anteris Technologies Global Corp. (Nasdaq: AVR, ASX: AVR), a global structural heart company, has announced the pricing of its public offering (the Offering) of 34,782,609 shares of its common stock at a public offering price of $US 5.75 per share. The gross proceeds to the Company from the Offering, prior to deducting underwriting discounts, commissions and estimated offering expenses, are expected to be approximately $US 200 million. The Offering is expected to close on January 22, 2026, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 5,217,391 shares from the Company at the public offering price, less underwriting discounts and commissions. Concurrently, Anteris has agreed to sell to Medtronic plc (through a wholly owned subsidiary) in a private placement exempt from the registration requirements of the Securities Act of 1933, up to $US 90.0 million of shares of common stock, subject to a minimum purchase of 16.0% and a maximum purchase of 19.99% of the number of shares of common stock outstanding after the Offering. Anteris intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents and the net proceeds from the Private Placement, to support the next stage of growth and advance execution of the Company's clinical strategy, including ongoing recruitment and study execution of the DurAVR® Transcatheter Heart Valve (DurAVR® THV) global pivotal trial for patients with severe aortic stenosis, expansion of manufacturing capabilities, and ongoing research and development for v2vmedtech, inc., with the balance allocated to working capital and other general corporate purposes.